سامية محمد مصطفى



شبكة المعلومات الحامعية

بسم الله الرحمن الرحيم



-Caro-

سامية محمد مصطفي



شبكة العلومات الحامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





سامية محمد مصطفى

شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسو

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعيدا عن الغيار



سامية محمد مصطفي



شبكة المعلومات الجامعية



المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة ا

سامية محمد مصطفى

شبكة المعلومات الحامعية



بالرسالة صفحات لم ترد بالأصل



NEUROPROTECTIVE EFFECTS OF VARIOUS DRUGS AGAINST NEURONAL DAMAGE

THESIS

Presented by

HANAN SALAH EL-DIN EL-ABHAR

Assistant Lecturer of Pharmacology
Faculty of Pharmacy, Cairo University

OF Dr. OF PHILOSOPHY IN

PHARMACEUTICAL SCIENCES


(PHARMACOLOGY)

FACULTY OF PHARMACY

CAIRO UNIVERSITY

B 0-70

1995





UNDER THE SUPERVISION OF

Prof. Dr. Samir F. Saad Prof. Dr. M. T. Khayyal Professor of Pharmacology and Head of Pharmacology Department Faculty of Pharmacy dairo University

Professor of Pharmacology Faculty of Pharmacy Cairo University

Prof. Dr. Dr. J. Krieglstein Professor of Pharmacology and Director of Institute for Pharmacology and Toxicology Philipps University Marburg, Germany

APPROVAL SHEET

Approved:

Committee in Charge:

(1) Jaar St.

(2)

(3)

Date: / / 1995.

To My Family,

For The Precious Years Taken From Family Life

ACKNOWLEDGEMENT

I wish to express my deepest appreciation and sincere thanks to Professor Dr. Samir F. Saad, Head of Pharmacology Department, Faculty of Pharmacy, Cairo University, for his kind supervision, encouragement, useful comments and guidance throughout the preparation of this work.

It is a pleasure to acknowledge with sincere thanks and appreciation, the kind help afforded to me by Professor Dr. M. T. Khayyal, Professor of Pharmacology, Faculty of Pharmacy, Cairo University. For him I am indebted, for his keen supervision, valuable assistance, for the precious time he devoted to me and for his forbearance through the burdensome process of proof-reading and revising. For him again I am obliged for his outstanding guidance and expert advice.

I am also greatly indebted to Professor Dr. Dr. Josef Krieglstein, Director of the Institute for Pharmacology and Toxicology, Philipps University, Marburg, Germany, for his enthusiastic supervision, valuable advice, encouragement and useful comments on the planning of the experiments, which were the corner stone in the practical part of this thesis. I would like to thank him also for providing me kindly with all the facilities that helped me to accomplish this work.

My special appreciation is also presented to **Professor Dr. Hans-Dieter Mennel**, Professor of Neuropathology, Department of Neuropathology, Philipps University, Marburg, Germany, for his kind help in carrying out the histopathological examinations.

My cordial thanks are extended to all my colleagues and staff members, with special reference to the technical division in the Institute for Pharmacology and Toxicology, Philipps University, Marburg, Germany, for their unforgettable cooperation and help, which made my stay in Marburg a thoroughly enjoyable and fruitful one.

Contents	Pages
1- Aim of Work	1
2- Introduction	
- Factors involved in ischaemia	5
- Neuroprotective agents in ischaemia	26
3- Materials and methods	34
4- Results	53
5-Discussion	89
6- Summary	110
7 References	113
8- Arabic summary	

List of Figures

	Pa
1- The major features of cell Ca ²⁺ metabolism as exemplified by events which	
very likely occur in many neurones	7
2- Diagram illustrating how activation of glutamate receptors open cation	
channels	11
3- The NMDA-receptor complex	13
4- The glutamate release and its uptake process	14
5- Schaematic diagram summarizing why glutamate uptake fails during brain	
anoxia	16
6- Diagram illustrating primary effects of depolarization, receptor activation	
and secondary effect of an increased intracellular Ca2+ concentration	21
7- Principle pathway leading to production of arachidonic acid metabolites and	
lipid mediators, following stimulation of phospholipase A ₂ or C	22
8- Serotonin pathways in rat brain	23
9- Metabolic pathway of paroxetine	29
10- Illustration of the site of removal of the temporalis muscle and the position	
of cranictomy in the MCA-O model in the rat	39
11- Demonstrates the MCA, its branches, and sites of occlusion	39
12- Schematic diagram for the infarcted areas at different coronal levels	42
13- Steps followed in the MCA-O method in the mouse	44
14- Effect of CRE-319 on the infarct volume, 48 hrs after MCA-O in the rat	
CRE-319 was given 1 hr before or immediately after MCA-O	54
15- Effect of CRE-319 on the infarct volume, 48 hrs after MCA-O in the rat.	
CRE-319 was given 1 & 2 hrs after MCA-O	55
16- Effect of CRE-319 on the infarct area, 48 hrs after MCA-O in the	
mouse. CRE-319 was given either immediately or 1/2 hr after MCA-O	56
17- Effect of CRE-319 on the infarct area, 48 hrs after MCA-O in the	
mouse. CRE-319 was given either 1 or 2 hrs after MCA-O	57
18- Effect of CRE-319, paroxetine and their combination on the infarct area,	
48 hrs after MCA-O in the mouse.	58
19- Effect of bilobalide on the infarct volume, 48 hrs after MCA-O in the rat	
Bilobalide was given in 2 forms in a dose of 5 mg/kg	60
20- Effect of bilobalide on the infarct volume, 48 hrs after MCA-O in the rat.	
Bilobalide was given in a dose of 10 mg/kg, 1 hr before MCA-O	61
21- Effect of bilobalide (5 mg/kg), EGb 761 (200 mg/kg) and their combina-	
tion on the infarct area, 48 hrs after MCA-O in the mouse	62
22- Effect of bilobalide (10 mg/kg), EGb 761 (400 mg/kg) and their combina-	
tion on the infarct area, 48 hrs after MCA-O in the mouse	63
23- Effect of EGb 761 injected by different routes on the infarct area, 48 hrs	
after MCA-O in the mouse	64
24- Effect of different dose levels of EGb 761 on the infarct area, 48 hrs	~ .
after MCA-O in the mouse	66
25- Effect of EGb 761 on the infarct area, 48 hrs after MCA-O in the mouse.	
EGb 761 was given in a dose of 50 mg/kg, p.o. for 7 days	67

. #	
j) L	
26- Effect	of EGb 761, insulin and their combination on the infarct volume, 48
	ter MCA-O in the rat
27- Effect	of nisoxetine on the infarct volume, 48 hrs after MCA-O in the rat
	of paroxetine on the infarct volume, 48 hrs after MCA-O in the rat
29- Effe¢i	of U-74389G on the infarct volume, 48 hrs after MCA-O in the
гаt	
	of postischaemic period on the infarct area in the mouse
JR.	louration in the cresyl violet stain restricted to the pertinent area of
	tex
32- I ne is	chaemic area appears as a pale area compared to the surroundings
	rp demarcation line separates between the infarcted area and the
· · · · · · · · · · · · · · · · · · ·	arance of a faint assembly of WBCs
	arance of the first fat granule cells (foam cells)
	ation of a broad rim of fat granule cells separating infarcted area and
	al brain tissue.(5 days after MCA-O)
37- Form	ation of a broad rim of fat granule cells separating infarcted area and
norma	al brain tissue.(5 days after MCA-O)
	ting of capillaries from the normal brain into the infarcted area
39- Increa	ase of connective tissue covering the infarction
	ase of connective tissue covering the infarction
,	onnective tissue zone tries to ensheath the infarction
	onnective tissue zone tries to ensheath the infarction
43- The c	apillaries and connective tissue directly invade the necrotic tissue
44- Effect	of dizocilpine on the infarct area, 48 hrs after MCA-O in the mouse.
45 500	City in the manage of the Annual Annu
	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse.
46- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse of dizocilpine on the infarct area, 10 days after MCA-O in the
46- Effect mouse	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the
46- Effect mouse 47- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the
46- Effect mouse 47- Effect mouse	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the
46- Effect mouse 47- Effect mouse 48- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the
46- Effect mouse 47- Effect mouse 48- Effect mouse	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated
46- Effect mouse 47- Effect mouse 48- Effect mouse 49- Effect	of dizocilpine on the infarct area, 5 days after MCA-O in the mouse. of dizocilpine on the infarct area, 10 days after MCA-O in the of dizocilpine on the infarct area, 20 days after MCA-O in the of dizocilpine on the infarct area, 2 months after MCA-O in the of postischaemic period on the infarct area in control untreated